NZ734881B2 - Anti-bacterial compositions - Google Patents
Anti-bacterial compositions Download PDFInfo
- Publication number
- NZ734881B2 NZ734881B2 NZ734881A NZ73488116A NZ734881B2 NZ 734881 B2 NZ734881 B2 NZ 734881B2 NZ 734881 A NZ734881 A NZ 734881A NZ 73488116 A NZ73488116 A NZ 73488116A NZ 734881 B2 NZ734881 B2 NZ 734881B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- composition
- acid
- product
- bacterial
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 352
- 230000000844 anti-bacterial Effects 0.000 title claims abstract description 83
- 239000011780 sodium chloride Substances 0.000 claims abstract description 23
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims abstract description 21
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 16
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 230000000699 topical Effects 0.000 claims description 36
- 239000000047 product Substances 0.000 claims description 33
- -1 excipient Substances 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 23
- 230000012010 growth Effects 0.000 claims description 22
- 241000894006 Bacteria Species 0.000 claims description 20
- 238000009472 formulation Methods 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 12
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N Undecylenic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 claims description 11
- 239000000969 carrier Substances 0.000 claims description 11
- 229960002703 undecylenic acid Drugs 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000004599 antimicrobial Substances 0.000 claims description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000004310 lactic acid Substances 0.000 claims description 10
- 235000014655 lactic acid Nutrition 0.000 claims description 10
- 239000000123 paper Substances 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 206010060945 Bacterial infection Diseases 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 244000052616 bacterial pathogens Species 0.000 claims description 8
- 239000000344 soap Substances 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 235000013355 food flavoring agent Nutrition 0.000 claims description 7
- 239000000375 suspending agent Substances 0.000 claims description 7
- 239000003599 detergent Substances 0.000 claims description 6
- 239000003973 paint Substances 0.000 claims description 6
- 239000004033 plastic Substances 0.000 claims description 6
- 229920003023 plastic Polymers 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 4
- 238000010348 incorporation Methods 0.000 claims description 4
- 230000002147 killing Effects 0.000 claims description 4
- 239000002324 mouth wash Substances 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 229940051866 Mouthwash Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 239000002453 shampoo Substances 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 239000000606 toothpaste Substances 0.000 claims description 3
- FVXBTPGZQMNAEZ-UHFFFAOYSA-N 3-amino-2-methylpropan-1-ol Chemical compound NCC(C)CO FVXBTPGZQMNAEZ-UHFFFAOYSA-N 0.000 claims description 2
- CBTVGIZVANVGBH-UHFFFAOYSA-N Aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 claims description 2
- 229940034610 Toothpaste Drugs 0.000 claims description 2
- 239000003139 biocide Substances 0.000 claims description 2
- 239000002781 deodorant agent Substances 0.000 claims description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 abstract description 12
- 230000036457 multidrug resistance Effects 0.000 abstract description 3
- 230000001717 pathogenic Effects 0.000 abstract description 3
- 244000052769 pathogens Species 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 description 38
- 241000700159 Rattus Species 0.000 description 37
- 200000000019 wound Diseases 0.000 description 34
- 241001465754 Metazoa Species 0.000 description 27
- 239000012491 analyte Substances 0.000 description 22
- 210000004369 Blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 241000588724 Escherichia coli Species 0.000 description 20
- 239000000463 material Substances 0.000 description 20
- 210000002966 Serum Anatomy 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- 230000000845 anti-microbial Effects 0.000 description 17
- 238000010790 dilution Methods 0.000 description 17
- 239000003242 anti bacterial agent Substances 0.000 description 16
- 230000001580 bacterial Effects 0.000 description 16
- 239000012085 test solution Substances 0.000 description 16
- 235000014113 dietary fatty acids Nutrition 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 239000000194 fatty acid Substances 0.000 description 15
- 150000004665 fatty acids Chemical class 0.000 description 15
- 239000000725 suspension Substances 0.000 description 14
- 230000001809 detectable Effects 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 201000009910 diseases by infectious agent Diseases 0.000 description 12
- 239000002609 media Substances 0.000 description 12
- 244000005700 microbiome Species 0.000 description 12
- 230000001603 reducing Effects 0.000 description 12
- 238000006722 reduction reaction Methods 0.000 description 12
- 210000004027 cells Anatomy 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 239000004698 Polyethylene (PE) Substances 0.000 description 10
- 210000003491 Skin Anatomy 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 210000002381 Plasma Anatomy 0.000 description 9
- 230000003115 biocidal Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 239000003755 preservative agent Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000002085 irritant Substances 0.000 description 8
- 230000002335 preservative Effects 0.000 description 8
- 235000010956 sodium stearoyl-2-lactylate Nutrition 0.000 description 8
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 7
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 7
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 7
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 7
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 7
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 7
- MYPYJXKWCTUITO-LYRMYLQWSA-N VANCOMYCIN Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 7
- 108010059993 Vancomycin Proteins 0.000 description 7
- 229960003165 Vancomycin Drugs 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000002054 inoculum Substances 0.000 description 7
- 229940079866 intestinal antibiotics Drugs 0.000 description 7
- 239000004006 olive oil Substances 0.000 description 7
- 235000008390 olive oil Nutrition 0.000 description 7
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 7
- 239000003765 sweetening agent Substances 0.000 description 7
- 210000001519 tissues Anatomy 0.000 description 7
- 229940028420 Bactroban Drugs 0.000 description 6
- 241000588747 Klebsiella pneumoniae Species 0.000 description 6
- MINDHVHHQZYEEK-HBBNESRFSA-N MUPIROCIN Chemical group C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-HBBNESRFSA-N 0.000 description 6
- 206010025482 Malaise Diseases 0.000 description 6
- 229960003128 Mupirocin Drugs 0.000 description 6
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 6
- 229940076185 Staphylococcus aureus Drugs 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drugs Drugs 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000003305 oral gavage Methods 0.000 description 6
- 210000000056 organs Anatomy 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000006150 trypticase soy agar Substances 0.000 description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical group O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 230000003522 irritant Effects 0.000 description 5
- 231100000021 irritant Toxicity 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 230000036961 partial Effects 0.000 description 5
- 231100000607 toxicokinetics Toxicity 0.000 description 5
- 231100000041 toxicology testing Toxicity 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- 206010013709 Drug ineffective Diseases 0.000 description 4
- 239000004150 EU approved colour Substances 0.000 description 4
- 241000194032 Enterococcus faecalis Species 0.000 description 4
- 241000194031 Enterococcus faecium Species 0.000 description 4
- 241001522878 Escherichia coli B Species 0.000 description 4
- 210000003195 Fascia Anatomy 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 4
- 229940045505 Klebsiella pneumoniae Drugs 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N Lauric acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- PGSADBUBUOPOJS-UHFFFAOYSA-N Neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 241000191940 Staphylococcus Species 0.000 description 4
- 210000002700 Urine Anatomy 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 125000004432 carbon atoms Chemical group C* 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229960002227 clindamycin Drugs 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- 238000007489 histopathology method Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 229940006093 opthalmologic coloring agents Diagnostic Drugs 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000008229 sterile water for irrigation Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 210000000601 Blood Cells Anatomy 0.000 description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N Chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 3
- 229960001076 Chlorpromazine Drugs 0.000 description 3
- 229940032049 Enterococcus faecalis Drugs 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 3
- 206010058667 Oral toxicity Diseases 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- 206010034972 Photosensitivity reaction Diseases 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 241000201788 Staphylococcus aureus subsp. aureus Species 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 210000003462 Veins Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001414 amino alcohols Chemical class 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 239000006161 blood agar Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000001586 eradicative Effects 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 230000003370 grooming Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229960003085 meticillin Drugs 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 231100000418 oral toxicity Toxicity 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 231100000018 phototoxicity Toxicity 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- 206010000496 Acne Diseases 0.000 description 2
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 229960003563 Calcium Carbonate Drugs 0.000 description 2
- 229940095731 Candida albicans Drugs 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N Clindamycin Chemical group CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 210000004087 Cornea Anatomy 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- 230000036882 MTD Effects 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 206010029803 Nosocomial infection Diseases 0.000 description 2
- 231100000261 OECD 432 In Vitro 3T3 NRU Phototoxicity Test Toxicity 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 2
- 229950008882 Polysorbate Drugs 0.000 description 2
- 229940037645 Staphylococcus epidermidis Drugs 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 229940076156 Streptococcus pyogenes Drugs 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- NWGKJDSIEKMTRX-HSACVWGTSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-HSACVWGTSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000001058 adult Effects 0.000 description 2
- 231100000494 adverse effect Toxicity 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 230000003385 bacteriostatic Effects 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 230000003902 lesions Effects 0.000 description 2
- 230000001795 light effect Effects 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 230000000813 microbial Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 230000003472 neutralizing Effects 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000000275 pharmacokinetic Effects 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 231100000119 phototoxicity / photoirritation testing Toxicity 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000000069 prophylaxis Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000002685 pulmonary Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 231100000161 signs of toxicity Toxicity 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 235000019801 trisodium phosphate Nutrition 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- VDPLLINNMXFNQX-UHFFFAOYSA-N (1-aminocyclohexyl)methanol Chemical compound OCC1(N)CCCCC1 VDPLLINNMXFNQX-UHFFFAOYSA-N 0.000 description 1
- QKGFFCDDDREERJ-UHFFFAOYSA-N (1-aminocyclooctyl)methanol Chemical compound OCC1(N)CCCCCCC1 QKGFFCDDDREERJ-UHFFFAOYSA-N 0.000 description 1
- PDNZJLMPXLQDPL-UHFFFAOYSA-N (1-aminocyclopentyl)methanol Chemical compound OCC1(N)CCCC1 PDNZJLMPXLQDPL-UHFFFAOYSA-N 0.000 description 1
- FIWSRSRCWYARAJ-SQOFCNSWSA-N (2R,3R,4R,5S)-hexane-1,2,3,4,5,6-hexol;(Z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O FIWSRSRCWYARAJ-SQOFCNSWSA-N 0.000 description 1
- IFIDGPUHWCUADA-UHFFFAOYSA-N 1-(2-aminophenyl)propan-1-ol Chemical compound CCC(O)C1=CC=CC=C1N IFIDGPUHWCUADA-UHFFFAOYSA-N 0.000 description 1
- GXMSOADYSNPWRB-UHFFFAOYSA-N 1-aminoheptan-3-ol Chemical compound CCCCC(O)CCN GXMSOADYSNPWRB-UHFFFAOYSA-N 0.000 description 1
- UWDQRLFJJPLBLU-UHFFFAOYSA-N 1-aminononan-3-ol Chemical compound CCCCCCC(O)CCN UWDQRLFJJPLBLU-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- NYVDHTLXVVFPHK-UHFFFAOYSA-N 2-(aminomethyl)hexan-1-ol Chemical compound CCCCC(CN)CO NYVDHTLXVVFPHK-UHFFFAOYSA-N 0.000 description 1
- NZRSZJGFBIHNBU-UHFFFAOYSA-N 2-(aminomethyl)octan-1-ol Chemical compound CCCCCCC(CN)CO NZRSZJGFBIHNBU-UHFFFAOYSA-N 0.000 description 1
- 230000035533 AUC Effects 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229940023476 Agar Drugs 0.000 description 1
- 229940061720 Alpha Hydroxy Acids Drugs 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 206010003997 Bacteraemia Diseases 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 1
- 229940052491 Bordetella pertussis Drugs 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 241000589513 Burkholderia cepacia Species 0.000 description 1
- 102100008034 C21orf91 Human genes 0.000 description 1
- 101710027714 C21orf91 Proteins 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940113118 Carrageenan Drugs 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 210000004289 Cerebral Ventricles Anatomy 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 230000037242 Cmax Effects 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229940047652 Ear Drops Drugs 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- 206010014665 Endocarditis Diseases 0.000 description 1
- 229940092559 Enterobacter aerogenes Drugs 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 210000002615 Epidermis Anatomy 0.000 description 1
- 210000000981 Epithelium Anatomy 0.000 description 1
- 229940083553 Erythromycin 500 MG Drugs 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N Ethylparaben Chemical group CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 229940012356 Eye Drops Drugs 0.000 description 1
- 230000036328 Free drug Effects 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940074045 Glyceryl Distearate Drugs 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 229940047650 Haemophilus influenzae Drugs 0.000 description 1
- 239000012593 Hanks’ Balanced Salt Solution Substances 0.000 description 1
- 229940037467 Helicobacter pylori Drugs 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N Hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000588749 Klebsiella oxytoca Species 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 208000002473 Lacerations Diseases 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L Magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 210000004379 Membranes Anatomy 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- 210000004400 Mucous Membrane Anatomy 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 230000036823 Plasma Levels Effects 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229940055033 Proteus mirabilis Drugs 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010039447 Salmonellosis Diseases 0.000 description 1
- 229940098362 Serratia marcescens Drugs 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 229940115939 Shigella sonnei Drugs 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 206010040872 Skin infection Diseases 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 229940083466 Soybean Lecithin Drugs 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229940037649 Staphylococcus haemolyticus Drugs 0.000 description 1
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 1
- 241000192087 Staphylococcus hominis Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229940030998 Streptococcus agalactiae Drugs 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 229940031000 Streptococcus pneumoniae Drugs 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- 229960001608 Teicoplanin Drugs 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229940118696 Vibrio cholerae Drugs 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000009632 agar plate Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic Effects 0.000 description 1
- 238000004164 analytical calibration Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 200000000017 bloodstream infection Diseases 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- QXJJQWWVWRCVQT-UHFFFAOYSA-K calcium;sodium;phosphate Chemical compound [Na+].[Ca+2].[O-]P([O-])([O-])=O QXJJQWWVWRCVQT-UHFFFAOYSA-K 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Chemical compound OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- KDLRVYVGXIQJDK-NOWPCOIGSA-N clindamycin Chemical group CN1C[C@H](CCC)C[C@H]1C(=O)NC(C(C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-NOWPCOIGSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 231100000269 corneal opacity Toxicity 0.000 description 1
- 231100000478 corneal permeability Toxicity 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 201000004624 dermatitis Diseases 0.000 description 1
- 230000000249 desinfective Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 201000003928 fungal infectious disease Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100001045 histological change Toxicity 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 244000052637 human pathogens Species 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 231100000058 in vitro skin irritation / corrosion testing Toxicity 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 239000011776 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000009906 meningitis Diseases 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 230000003641 microbiacidal Effects 0.000 description 1
- 239000012184 mineral wax Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004690 mucosal barrier Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 230000000541 pulsatile Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003595 spectral Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
Antibacterial compositions comprising at least one unsaturated fatty acid or a pharmaceutically acceptable salt thereof; at least one alpha-hydroxy acid or a pharmaceutically acceptable salt thereof; and at least one amino alcohol. The compositions have broad-spectrum antibacterial activity, including on pathogens displaying multi-drug resistance. ng on pathogens displaying multi-drug resistance.
Description
ANTI-BACTERIAL COMPOSITIONS
FIELD OF THE INVENTION
This invention pertains to the field of anti-bacterial compositions and, in particular, to anti-
bacterial compositions comprising one or more fatty acids, one or more hydroxy acids and
one or more amino alcohols.
BACKGROUND OF THE INVENTION
There is currently an urgent need for compounds and/or compositions with broad-spectrum
anti-bacterial activity. The increasing incidence of infectious disease caused by bacterial
pathogens in both communities and hospitals is a worldwide health concern. Severe invasive
infections are reported as the main complication in cancer therapies, as well as bone marrow
transplantation and major surgeries. Infection is also a major concern for immuno-
compromised patients with haematological malignancy and/or AIDS.
Amongst bacterial pathogens, there has recently been a significant increase of multi-drug
resistance. For example, strains of Staphylococcus aureus (methicillin-resistant or MRSA)
and coagulase-negative Staphylococci (CoNS) have become resistant to the most commonly
used antibiotics, such that the only available antibiotics uniformly active against them are
the glycopeptides, vancomycin and teicoplanin. S. aureus is one of the leading causes of
hospital-acquired bacteremia capable of causing a wide range of diseases ranging from
superficial skin infections to potentially fatal illnesses such as bloodstream infection,
endocarditis and pneumonia (Diekema et al. Clin. Infect. Dis. 2001, 32:S114-132). Other
human pathogens that have begun to develop resistance to multiple antibiotics include
Streptococcus pneumoniae (the leading cause of nosocomial infections) and Pseudomonas
aeruginosa, Haemophilus influenzae and Moraxella catarrhalis (the most common
community-acquired respiratory pathogens; Hoban et al. Clin. Infect. Dis. 2001, 32:S81-93).
These multidrug resistant bacteria (“superbugs”) are not restricted to hospitals alone and
they can be found in diverse settings including daycares, schools, prisons, sports facilities,
airports, healthcare facilities, retirement homes, etc. Paper and plastics are indispensable to
society and therefore need to be treated with antimicrobials to assist in the elimination of
these ”superbugs”.
Thus, new anti-bacterial compositions are needed to address both the growing resistance
amongst microbes to present therapies and the general lack of efficacy of existing antibiotics
against microorganisms.
In the cosmetics and food industry also there is a constant need for agents having
antimicrobial properties, in particular for the preservation of products which are otherwise
perishable, but also for direct cosmetic or therapeutic treatment of microorganisms which
can have an adverse influence on the human or animal body. Reference may be made by
way of example to microorganisms which can cause body odour, acne, mycoses or the like.
The antimicrobial properties of free fatty acids have been known for many years (Kabara J.
et al. Antimicrobial Agents and Chemotherapy, July 1972; 2(1): pp 23 - 28). Bergson et al.
(Antimicrobial Agents and Chemotherapy, November 2001, pp 3209 - 3212), reported that
both capric and lauric acid were effective in killing the yeast Candida albicans. Sun et al.
(Chemico-Biological Interactions 140 (2002), pp185-198), identified the superior
microbicidal properties of caprylic, capric and lauric acid, concluding that lauric was most
potent against gram positive bacteria while caprylic was optimal against gram negative
organisms.
discloses antimicrobial compositions comprising free fatty acids
emulsified with membrane lipids or hydrolysed derivatives thereof, and pharmaceutical
formulations comprising same. The compositions can be used in the treatment or
prophylaxis of microbial infections. They can also regulate the rate of blood clotting
rendering them suitable for incorporation in catheter locking solutions and for use in wound
care.
WO 99/51218 discloses a biocidal composition of a blend of acids substantially free of
benzoic acid or a derivative thereof and comprising a mixture of lactic acid and at least one
other acid selected from formic acid, acetic acid and propionic acid. In GB 1,194,863
preservative composition for crops is described comprising 70 wt. % phosphoric acid, 20 wt.
% propionic acid and 5 wt. % lactic acid.
US7727568 discloses an antimicrobial composition comprising a mixture of at least 20wt.
% lactic acid or a derivative thereof and an inorganic acid selected from a nitrogen, sulfur,
and phosphorous acid, and mixtures thereof for use in animal nutrition. The composition can
further comprise at least one other acid selected from acetic acid, fumaric acid, gluconic
acid, (iso)butyric acid, sorbic acid, (iso)valeric acid, maleic acid, malic acid, capronic acid,
benzoic acid, and citric acid.
WO2014/035246 discloses antimicrobial compositions comprising at least one free fatty
acid or a derivative and/or a pharmaceutically acceptable salt thereof, at least one carboxylic
acid or a pharmaceutically acceptable salt thereof; and/or at least one carbohydrate or a
pharmaceutically acceptable salt thereof, wherein the carbohydrate is selected from a
hydrogenated carbohydrate, a monosaccharide, a disaccharide, a polysaccharide and
combinations thereof. The compositions of this reference are aimed to provide an
antimicrobial composition for treating or preventing the first stage in pathogenesis in order
to prevent infections. This reference also discloses that a composition comprising a
combination of at least one free fatty acid and at least one carboxylic acid exhibit
disinfecting properties, whereas the combination of at least one free fatty acid and at least
one carbohydrate, optionally in combination with at least one carboxylic acid, exerts a dual
antimicrobial effect.
WO2009/140062 discloses use of amino alcohols as additives for hydrocarbonaceous
compositions, such as petroleum and fuels, to improve the corrosion and microbial
resistance of hydrocarbonaceous compositions. This reference also discloses that the
particularly preferred amino alcohols for the desired result are 2-aminomethyl-l-hexanol,
2- aminoethyl-l-pentanol, 2-aminomethyl-l-octanol, 2-aminoethyl-l-heptanol, 2-
aminopropyl-l-hexanol, (l-aminocyclohexyl)methanol, (l-aminocyclooctyl)methanol, 2-
aminophenyl-l-propanol, (l-aminocyclopentyl)methanol, and mixtures thereof.
There remains a need for antimicrobial compounds and/or compositions that have improved
and/or broad spectrum anti-bacterial activity.
This background information is provided for the purpose of making known information
believed by the applicant to be of possible relevance to the present invention. No admission
is necessarily intended, nor should be construed, that any of the preceding information
constitutes prior art against the present invention.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a novel composition having improved anti-
bacterial activity; and/or to at least provide the public with a useful choice. Described
herein is an antibacterial composition comprising at least one unsaturated fatty acid or a
pharmaceutically acceptable salt thereof, wherein the free fatty acid is selected from a free
fatty acid having from 6 to 16 carbon atoms; at least one alpha-hydroxy acid or a
pharmaceutically acceptable salt thereof; and at least one amino alcohol.
In accordance with an aspect of the present invention, there is provided an antibacterial
composition comprising:
a) about 50% to about 70% of an unsaturated fatty acid or a pharmaceutically
acceptable salt thereof, by weight of the total weight of the composition,
wherein the unsaturated fatty acid is undecylenic acid;
b) about 20% to about 30% of lactic acid or a pharmaceutically acceptable salt
thereof, by weight of the total weight of the composition;
c) about 10% to about 15% of at least one amino alcohol, by weight of the total
weight of the composition, wherein the amino alcohol has a formula:
OH NH
R C C R
1 3 2 4 2
wherein R and R are each independently H or alkyl, R and R are each H, or R
4 2 4
and R are each C -C alkyl, or R is methyl and R is CH OH;
1 6 2
wherein the composition is free of additional antimicrobial or biocidal agents.
In accordance with another aspect of the present invention, there is provided a
pharmaceutical formulation comprising a composition as defined above, and a
pharmaceutically acceptable carrier.
In accordance with another aspect of the present invention, there is provided a use of the
composition as defined above in the preparation of a formulation for inhibiting growth
and/or proliferation of bacteria.
Also described is the use of the pharmaceutical formulation of the present invention for
inhibiting growth and/or proliferation of a microbe.
In accordance with another aspect of the present invention, there is provided a method of
killing and/or inhibiting the growth of microbes on a non-living substrate comprising
applying an effective amount of the antibacterial composition as defined above.
In accordance with another aspect of the present invention, there is provided a use of the
composition as defined above in the preparation of a formulation for the treatment or
prevention of a bacterial infection in a mammal in need thereof.
In accordance with another aspect of the present invention, there is provided a use of the
composition as defined above for incorporation into a cosmetic product, personal care
product, cleanser, polish, paint, spray, soap, detergent, paper product or plastic product.
In accordance with another aspect of the present invention, there is provided a use of the
composition as defined above in the preparation of a formulation for the treatment or
prevention of a bacterial infection, or a disease or disorder associated therewith, in a subject
in need of such therapy.
In accordance with another aspect of the present invention, there is provided a transdermal
patch comprising the composition as defined above.
In accordance with another aspect of the present invention, there is provided a personal care
product comprising the antibacterial composition as defined above.
In accordance with another aspect of the present invention, there is provided a household
product comprising the antibacterial composition as defined above.
In accordance with another aspect of the present invention, there is provided a paper product
comprising the antibacterial composition as defined above.
In accordance with another aspect of the present invention, there is provided a plastic
product comprising the antibacterial composition as defined above.
In the description in this specification reference may be made to subject matter that is not
within the scope of the claims of the current application. That subject matter should be
readily identifiable to a person skilled in the art and may assist in putting into practice the
invention as defined in the claims of this application.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides novel anti-bacterial compositions and uses thereof. In the
context of the present invention, the term “anti-bacterial” refers to the inhibition, prevention
or eradication of the growth or proliferation of bacteria and to the inhibition, prevention or
eradication of the growth or proliferation of bacterial cells.
Definitions
Unless defined otherwise, all technical and scientific terms used herein have the same
meaning as commonly understood by one of ordinary skill in the art to which this invention
pertains.
The term “alkyl” refers to a straight chain or branched, alkyl group of one to ten carbon
atoms. This term is further exemplified by such groups as methyl, ethyl, n-propyl, i-propyl,
n-butyl, t-butyl, l-butyl (or 2-methylpropyl), and the like.
The term “amino” refers to the group NRR', where R and R' may independently be
hydrogen, lower alkyl, or substituted alkyl.
The terms “therapy” and “treatment,” as used interchangeably herein, refer to an
intervention performed with the intention of alleviating the symptoms associated with,
preventing the development of, or altering the pathology of a disease, disorder or condition.
Thus, the terms therapy and treatment are used in the broadest sense, and include the
prevention (prophylaxis), moderation, management, reduction, or curing of a disease,
disorder or condition at various stages. Prevention or reduction of the progression of a
disease, disorder or condition is encompassed by these terms. Also encompassed by these
terms is an intervention resulting in an alteration of physiology and/or biochemistry of a
living subject. Those in need of therapy/treatment include those already having the disease,
disorder or condition as well as those prone to, or at risk of developing, the disease, disorder
or condition and those in whom the disease, disorder or condition is to be prevented. The
therapeutic application of compounds of the invention, therefore, refers to a therapy or
treatment, as defined herein.
The terms “subject” or “patient,” as used herein, refer to an animal in need of treatment,
including humans and other mammals.
Administration of the compostion of the present invention “in combination with” one or
more further therapeutic agents, is intended to include simultaneous (concurrent)
administration and consecutive administration. Consecutive administration is intended to
encompass various orders of administration of the therapeutic agent(s) and the compound(s)
to the subject.
The term “inhibit,” as used herein, means to reduce, halt or hold in check, and thus
inhibition may be complete or partial and may be of short or long term duration. The term
may be used in the context of inhibiting a process or action already begun or it may be used
in the context of inhibiting initiation of a process or action.
As used herein, the term “about” refers to approximately a +/-10% variation from a given
value. It is to be understood that such a variation is always included in any given value
provided herein, whether or not it is specifically referred to.
The Compositions
Described herein is an antibacterial composition comprising at least one unsaturated fatty
acid or a pharmaceutically acceptable salt thereof; at least one alpha-hydroxy carboxylic
acid or a pharmaceutically acceptable salt thereof; and at least one amino alcohol.
The unsaturated fatty acids described herein have from 6 to 16 carbon atoms, preferably the
free fatty acid has from 8 to 12 carbon atoms. In one embodiment, the free fatty acid is
undecylenic acid.
The alpha hydroxy acids described herein can be selected from glycolic acid, lactic acid,
citric acid, mandelic acid, oxalic acid, and malonic acid. In one embodiment, the alpha
hydroxy acid is lactic acid.
The amino alcohol described herein can have a formula:
1 3 2 4
wherein R and R are each independently H, linear or branched alkyl, R and R are each
independently H, linear or branched alkyl; and R5 is absent or is a C -C alkylene.
In one embodiment, in the formula (I) above, R5 is absent, R2 and R4 are both C1-C6 alkyl.
In one embodiment, the amino alcohol is 2-aminomethylpropanol.
In one embodiment, in the formula (I) above, R5 is absent, R2 is C1-C6 alkyl and R4 is
CH OH.
In one embodiment, the amino alcohol is amino methyl propane diol (AMPD).
In one embodiment, the amino alcohol is monoethanolamine (MEA).
The individual concentrations of unsaturated fatty acid, alpha hydroxy acid and amino
alcohol can be in the range of about 5% to about 90% by weight of the total weight of the
composition.
In one embodiment the concentration of the unsaturated fatty acid is about 5%, 10%, 15%,
%, 25%, 30%, 235%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or a
percentage between any two of these values.
In one embodiment the concentration of the alpha hydroxy acid is about 5%, 10%, 15%,
%, 25%, 30%, 235%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or a
percentage between any two of these values.
In one embodiment the concentration of the amino alcohol is about 5%, 10%, 15%, 20%,
%, 30%, 235%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or a
percentage between any two of these values.
In one embodiment, in the composition described herein the amount of alpha hydroxy acid
is in the range of about 10% to about 40% by weight of the total weight of the composition,
the amount of unsaturated fatty acid is in the range of about 40% to about 80% by weight of
the total weight of the composition, and the amount of amino alcohol is in the range of about
% to about 25% by weight of the total weight of the composition. In one embodiment, in
the composition described herein the amount of alpha hydroxy acid is in the range of about
% to about 30% by weight of the total weight of the composition, the amount of
unsaturated fatty acid is in the range of about 50% to about 70% by weight of the total
weight of the composition, and the amount of amino alcohol is in the range of about 10% to
about 15% by weight of the total weight of the composition. In one embodiment, in the
composition described herein the amount of alpha hydroxy acid is in the range of about 10%
to about 15% by weight of the total weight of the composition, the amount of unsaturated
fatty acid is in the range of about 50% to about 70% by weight of the total weight of the
composition, and the amount of amino alcohol is in the range of about 20% to about 30% by
weight of the total weight of the composition
In one embodiment, the composition described herein comprises about 28.00 wt.% of alpha
hydroxy acid, about unsaturated fatty acid 58.00 wt.% and about 14.00 wt. % of amino
alcohol (95%). In one embodiment, the composition described herein comprises about
.00 wt.% of alpha hydroxy acid, about unsaturated fatty acid 55.00 wt.% and about 20.00
wt. % of amino alcohol (95%). In one embodiment, the composition described herein
comprises about 30.00 wt.% of alpha hydroxy acid, about unsaturated fatty acid 60.00 wt.%
and about 10.00 wt. % of amino alcohol (95%).
The antibacterial composition may further comprise at least one viscosity-enhancing agent,
i.e. thickening agent. Preferably the viscosity-enhancing agent is selected from xanthan
gum, alginic acid, agar, carrageenan, locust bean gum, pectin, cellulose derivatives, gelatin
and combinations thereof.
The antibacterial composition may comprise at least one emulsifying agent, such as
polysorbate (Tween) 20, polysorbate 40, polysorbate 60, polysorbate 80, polyoxyethylene
glycol alkyl ethers, glucoside alkyl ethers, polyoxyethylene glycol octylphenol ethers,
polyoxyethylene glycol alkylphenol ethers, glycerol alkyl esters, poloxamers, polyoxyl
castor oil, and combinations thereof. More preferably the emulsifying agent is polysorbate
Uses of the Anti-Bacterial Compositions
The present invention provides for the use of the compositions disclosed herein for the
inhibition, prevention or eradication of the growth and/or proliferation of bacteria, either
alone or in combination with known anti-microbial agents.
In one embodiment, the present invention provides a method of inhibiting bacterial growth
by contacting a bacterium with an effective amount of a composition as disclosed herein.
The compositions have broad spectrum anti-bacterial activity, in which case they may be
used against gram-positive and/or gram-negative bacteria.
Examples of gram-positive bacteria include, Clostridium difficile, Clostridium perfringens-
vegetative cells, Clostridium sporogenes-vegetative cells, Enterococcus faecalis-
vancomicyn resistant (VRE), Enterococcus faecium, Micrococcus luteus, Mycobacterium
smegmatis, Staphylococcus aureus, Staphylococcus aureus-methicillin resistant (MRSA),
Staphylococcus aureus-vancomicyn resistant (VRSA), Staphylococcus epidermidis,
Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus,
Streptococcus agalactiae, Streptococcus pneumonia, Streptococcus pneumoniae-Drug
Resistant, Streptococcus pyogenes, Streptococcus-Group A-Erythromycin-resistant,
Streptococcus-Group B-Clindamycin-resistant and Pseudomonas aeruginosa, Streptococcus
pyogenes and/or Streptococcus faecalis.
Examples of gram-negative bacteria include Acinetobacter baumannii, Acinetobacter - multi
drug resistant, Bacteroides fragilis, Bordetella pertussis, Burkholderia cepacia,
Camplylobacter species, Camplylobacter - drug resistant, Enterobacter aerogenes,
Enterobacteriaceae (ESBLs), Enterobacteriaceae - carbapenem-resistant, Escherichia coli
(cfu/g) 4.4×10 , Escherichia coli (E.coli)-(Resistant), Haemophilus influenza, Helicobacter
pylori, Klebsiella oxytoca, Klebsiella pneumoniae pneumoniae (CRE), Neisseria
gonorrhoeae, Neisseria gonorrhoeae-drug resistant, Neisseria meningitides, Proteus
mirabilis, Pseudomonas aeruginosa (cfu/g) 3.5x10 , Pseudomonas aeruginosa (Regular),
Pseudomonas aeruginosa - multi drug resistant, Salmonella-non-typhoidal-drug resistant,
Salmonella typhi, Salmonella typhi-drug resistant, Serratia marcescens, Shigella sonnei,
Shigella-drug-resistant, Vibrio cholerae, Enterobacter, and/or Klebsiella pneumonia.
In one embodiment, examples of bacteria that may be inhibited by the compositions of the
present invention include, but are not limited to, Enterobacter faecalis, Enterococcus
faecium, Escherichia coli, Escherichia coli O157:H7, Escherichia coli (cfu/g) 4.4×10 ,
Staphylococcus aureus, Staphylococcus aureus K147, Staphylococcus epidermidis,
Pseudomonas aeruginosa and Klebsiella pneumonia.
It is well-established in the field of microbiology that many multidrug-resistant strains of
bacteria have emerged in the recent past and will continue to emerge with the continued use
of standard antibiotics. Examples of currently known resistant strains of bacteria include
methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant
Enterococcus faecium.
In one embodiment, the compositions of the present invention can be used to inhibit growth
of such multidrug-resistant strains. In one embodiment, the compositions of the present
invention are used to inhibit the growth of MRSA and/or Enterococcus faecium.
In one embodiment, the compositions of the present invention are used in the preparation of
antibiotic compositions.
The compositions of the present invention can be used as the active ingredient in anti-
bacterial cleansers, polishes, paints, sprays, soaps, or detergents. In such cases, antibacterial
composition of the present invention can generally be used in quantities of between about
0.1% and about 20% by weight of the final product. In one embodiment, the amount of
antibacterial composition is about 0.1% to 5% by weight. In one embodiment the amount of
antibacterial composition is about 0.3% to about 5% by weight.
These compositions can also be included as an anti-bacterial agent in cosmetic, personal
care, household and industrial products, for example, to improve shelf-life by inhibiting the
growth of microbes within the products.
The compositions may be formulated for application to surfaces to inhibit the growth of a
bacterial species thereon, for example, surfaces such as countertops, desks, chairs,
laboratory benches, tables, floors, sinks, showers, toilets, bathtubs, bed stands, tools or
equipment, doorknobs and windows. Alternatively, the compositions may be formulated for
laundry applications, for example, for washing clothes, towels, sheets and other bed linen,
washcloths or other cleaning articles.
The antibacterial cleansers, polishes, paints, sprays, soaps, or detergents according to the
present invention can optionally contain suitable solvent(s), carrier(s), thickeners, pigments,
fragrances, deodorisers, emulsifiers, surfactants, wetting agents, waxes, or oils. The
cleansers, polishes, paints, sprays, soaps, and detergents according to the present invention
are useful in institutions, such as in hospital settings for the prevention of nosocomial
infections, as well as in home settings.
In addition, the invention contemplates the use of the compositions in formulations to kill or
inhibit the growth of bacterial species in food preparations, or to sterilise surgical and other
medical equipment and implantable devices, including prosthetic joints. The compositions
can also be formulated for use in the in situ sterilisation of indwelling invasive devices such
as intravenous lines and catheters, which are often foci of infection.
The present invention further contemplates the use of these compositions as the active
ingredient in personal care items, such as soaps, deodorants, shampoos, mouthwashes,
toothpastes, and the like. Many compositions used in personal care applications are
susceptible to bacterial growth and it is thus desirable to incorporate into these compositions
an effective anti-bacterial material.
In one embodiment, the present invention provides a formulation containing a composition
as defined herein for external use as a pharmaceutically acceptable skin cleanser. In one
embodiment, the compositions of the present invention can also be used as dermocosmetic
compositions.
The anti-bacterial agent may be incorporated into the personal care formulation using
techniques known in the art. Thus, the anti-bacterial agent may be added to the personal care
formulation as a solution, emulsion or dispersion in a suitable liquid medium. Alternatively,
the anti-bacterial agent may be added, undiluted, to the personal care formulation or may be
added with a solid carrier or diluent. The anti-bacterial agent may be added to the pre-
formed personal care formulation or may be added during the formation of the personal care
formulation, either separately or premixed with one of the other components of the
formulation.
The antibacterial composition of the present invention can generally be used in quantities of
between 0.1% and 20% by weight of the personal care compositions. In one embodiment,
the amount of antibacterial composition is between 0.1% and 5% by weight. In one
embodiment the amount of antibacterial composition is about 0.3% to about 5% by weight.
Pharmaceutical Formulations and Administration of Anti-Bacterial Compositions
For use as therapeutic agents in the treatment of bacterial infections, or disorders or diseases
associated therewith in a subject, the anti-bacterial compositions of the present invention are
typically formulated prior to administration. Therefore, the present invention provides
pharmaceutical formulations comprising one or more compositions of the present invention
and a pharmaceutically-acceptable carrier, diluent, or excipient. The present pharmaceutical
formulations are prepared by standard procedures using well-known and readily available
ingredients. In making the compositions of the present invention, the active ingredient will
usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, and may
be in the form of a capsule, sachet, paper, or other container.
The pharmaceutical formulations comprising the anti-bacterial compositions according to
the present invention may be formulated in a number of ways depending upon the desired
treatment and upon the area to be treated. Administration may be topical (including
ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary,
e.g. by inhalation or insufflation of powders or aerosols, including by nebulizer;
intratracheal, intranasal, epidermal and transdermal, oral or parenteral. Parenteral
administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or
intramuscular injection or infusion; or intracranial, e.g. intrathecal or intraventricular,
administration.
For administration to an individual for the treatment of an infection or disease, the present
invention also contemplates the formulation of the pharmaceutical formulations comprising
the anti-bacterial composition into oral dosage forms such as tablets, capsules and the like.
For this purpose, the composition can be combined with conventional carriers, such as
magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch,
gelatine, tragacanth, methylcellulose, sodium carboxymethyl-cellulose, low melting wax,
cocoa butter and the like. Diluents, flavouring agents, solubilizers, lubricants, suspending
agents, binders, tablet-disintegrating agents and the like can also be employed, if required.
The anti-microbial compositions can be encapsulated with or without other carriers. In
accordance with the present invention, the proportion of anti-bacterial composition(s) in any
solid and liquid formulation will be at least sufficient to impart the desired activity to the
individual being treated upon oral administration. The present invention further
contemplates parenteral injection of the anti-bacterial compositions, in which case the
compositions are formulated as a sterile solution containing other solutes, for example,
enough saline or glucose to make the solution isotonic.
For administration by inhalation or insufflation, the anti-microbial compositions can be
formulated into an aqueous or partially aqueous solution, which can then be utilized in the
form of an aerosol. Aqueous formulations of the anti-bacterial compositions of the present
invention may also be used in the form of ear or eye drops, or ophthalmic solutions. The
present invention further contemplates topical use of the anti-bacterial compositions. For
this purpose they can be formulated as dusting powders, creams or lotions in
pharmaceutically acceptable vehicles, which are applied to affected portions of the skin.
Compositions intended for oral use may be prepared according to procedures known in the
art for the manufacture of pharmaceutical formulations and such formulations may further
contain one or more sweetening agents, flavouring agents, colouring agents, preserving
agents, or a combination thereof, in order to provide pharmaceutically elegant and palatable
preparations. Tablets typically contain the anti-bacterial composition(s) in admixture with
non-toxic pharmaceutically acceptable excipients suitable for the manufacture of tablets,
such as inert diluents, for example, calcium carbonate, sodium carbonate, lactose, calcium
phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn
starch, or alginic acid; binding agents, for example, starch, gelatine or acacia, and
lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be
uncoated or they may be coated by known techniques to delay disintegration and absorption
in the gastrointestinal tract and thereby provide a sustained action over a longer period. For
example, a time delay material such as glyceryl monostearate or glyceryl distearate may be
employed.
Formulations for oral use may also be presented as hard gelatine capsules wherein the anti-
bacterial composition(s) is mixed with an inert solid diluent, for example, calcium
carbonate, calcium phosphate or kaolin, or as soft gelatine capsules wherein the active
ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or
olive oil.
Aqueous suspensions typically contain the anti-bacterial composition(s) in admixture with
excipients suitable for the manufacture of aqueous suspensions, such as suspending agents
(for example, sodium carboxylmethylcellulose, methyl cellulose, hydropropylmethyl
cellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia);
dispersing or wetting agents such as a naturally-occurring phosphatide (for example,
lecithin), or condensation products of an alkylene oxide with fatty acids (for example,
polyoxyethylene stearate), or condensation products of ethylene oxide with long chain
aliphatic alcohols (for example, hepta-decaethyleneoxycetanol), or condensation products of
ethylene oxide with partial esters derived from fatty acids and a hexitol (for example,
polyoxyethylene sorbitol monooleate), or condensation products of ethylene oxide with
partial esters derived from fatty acids and hexitol anhydrides (for example, polyethylene
sorbitan monooleate). The aqueous suspensions may further contain one or more
preservatives, for example, ethyl, or n-propyl-p-hydroxy benzoate; one or more colouring
agents; one or more flavouring agents, or one or more sweetening agents, such as sucrose or
saccharin, or a combination thereof.
Oily suspensions may be formulated by suspending the anti-bacterial composition(s) in a
vegetable oil, for example, peanut oil, olive oil, sesame oil or coconut oil, or in a mineral oil
such as liquid paraffin. The oily suspensions may contain a thickening agent, for example
beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above,
and flavouring agents may be added to provide palatable oral preparations. These
compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the
addition of water provide the anti-bacterial composition in admixture with a dispersing or
wetting agent, suspending agent and one or more preservatives. Suitable dispersing or
wetting agents and suspending agents are exemplified by those mentioned above.
Additional excipients, for example, sweetening, flavouring and colouring agents, may also
be present.
Pharmaceutical formulations of the present invention may also be in the form of oil-in-water
emulsions. The oil phase may be a vegetable oil, for example, olive oil or peanut oil, or a
mineral oil, for example, liquid paraffin, or mixtures thereof. Suitable emulsifying agents
may be naturally-occurring gums (for example, gum acacia or gum tragacanth); naturally-
occurring phosphatides (for example, soy bean lecithin), and esters or partial esters derived
from fatty acids and hexitol anhydrides (for example, sorbitan monooleate), and
condensation products of the partial esters with ethylene oxide (for example,
polyoxyethylene sorbitan monooleate). The emulsions may also contain sweetening and
flavouring agents.
Syrups and elixirs may be formulated with sweetening agents, for example, glycerol,
propylene glycol, sorbitol or sucrose. Such formulations may also contain one or more
demulcents, preservatives or flavouring and colouring agents, or combinations thereof.
The pharmaceutical formulations may be in the form of a sterile injectable aqueous or
oleaginous suspension. This suspension may be formulated according to known art using
suitable dispersing or wetting agents and suspending agents as described above. The sterile
injectable preparation may also be a solution or a suspension in a non-toxic, parentally
acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the
acceptable vehicles and solvents that may be employed are water, Ringer's solution and
isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally
employed as a solvent or suspending medium. Typically, a bland fixed oil is employed for
this purpose such as a synthetic mono- or diglyceride. In addition, fatty acids such as oleic
acid find use in the preparation of injectables. Adjuvants, such as local anaesthetics,
preservatives and buffering agents, may also be included in the injectable formulation.
The composition(s) of the present invention may be administered, together or separately, in
the form of suppositories for rectal or vaginal administration of the composition. These
compositions can be prepared by mixing the composition with a suitable non-irritating
excipient which is solid at ordinary temperatures but liquid at the rectal/vaginal temperature
and will therefore melt to release the composition. Examples of such materials include
cocoa butter and polyethylene glycols.
Another formulation of the present invention employs transdermal delivery devices
(“patches”). Such transdermal patches may be used to provide continuous or discontinuous
administration/application of the anti-bacterial compositions of the present invention in
controlled amounts. The construction and use of transdermal patches for the delivery of
pharmaceutical agents is well known in the art (see, for example, U.S. Patent No. 5,023,252;
issued Jun. 11, 1991, incorporated herein by reference in its entirety). Such patches may be
constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
In one embodiment, the composition(s) of the present invention can be incorporated into
medical dressings such as Tegaderm pad from 3M (which act as traditional sponge gauze, a
bacterial barrier just helping to reduce the risk of infection). In Tegaderm structure, the
main biocompatible wound dressing part is made of cellulose paper fibre coated with
silicone material, and all supporting and adhering parts are made of synthetic materials such
as: polyethylene, polyurethane, polyester and acrylate polymer.
It may be desirable or necessary to introduce the pharmaceutical formulations to the brain,
either directly or indirectly. Direct techniques usually involve placement of a drug delivery
catheter into the host's ventricular system to bypass the blood-brain barrier. An example of
such an implantable delivery system, used for the transport of biological factors to specific
anatomical regions of the body, is described in U.S. Patent No. 5,011,472, incorporated
herein by reference in its entirety.
The dosage of the anti-bacterial composition to be administered is not subject to defined
limits, but will usually be an effective amount. In general, the dosage will be the equivalent,
on a molar basis, of the pharmacologically active free form produced from a dosage
formulation upon the metabolic release of the active free drug to achieve its desired
pharmacological and physiological effects. The pharmaceutical compositions are typically
formulated in a unit dosage form, each dosage containing from, for example, about 0.05 to
about 100 mg of the anti-bacterial composition. The term “unit dosage form” refers to
physically discrete units suitable as unitary dosages for administration to human subjects
and other animals, each unit containing a predetermined quantity of anti-bacterial
composition calculated to produce the desired therapeutic effect, in association with a
suitable pharmaceutical excipient.
Typical daily dosages of the anti-bacterial compositions fall within the range of about 0.01
to about 200 mg/kg of body weight in single or divided dose. However, it will be
understood that the amount of the composition actually administered will be determined by
a physician, in the light of the relevant circumstances, including the condition to be treated,
the chosen route of administration, the actual composition administered, the age, weight,
and response of the individual patient, and the severity of the patient's symptoms, and
therefore the above dosage ranges are not intended to limit the scope of the invention in any
way. In some instances dosage levels below the lower limit of the aforesaid range may be
more than adequate, while in other cases still larger doses may be employed without causing
any harmful side effect, for example, by first dividing larger doses into several smaller doses
for administration throughout the day.
Compositions of the present invention formulated for topical administration are suitable in
the treatment and/or prevention of bacterial infections of the skin and mucosa.
Topical pharmaceutical and/or dermocosmetic formulations according to the invention
comprise the antibacterial composition mixed with one or more suitable excipients and may
be, for example, in the form of cream, ointment, gel, gum, toothpaste, mouthwash or
shampoo.
The pharmaceutical formulations and/or the dermocosmetic formulations can comprise
about 0.1% to about 20% by weight of the antibacterial composition of the present
invention. In one embodiment, the amount of antibacterial composition is about 0.1% to
about 10% by weight. In one embodiment, the amount of antibacterial composition is about
0.1% to about 5% by weight. In one embodiment the amount of antibacterial composition is
about 0.3% to about 2% by weight.
Examples of suitable excipients that may be used in the compositions according to the
invention are solvents, diluents, gliding agents, preservatives, gums, sweeteners, coating
agents, binders, disintegrating agents, lubricants, suspending agents, dispersing agents,
colorants, flavouring agents, non-stick agents, surfactants, plasticisers, emulsifiers, chelating
agents and emollients.
The solvent preferably used is water, but alcohols or other organic solvents may also be
used, possibly mixed with water.
The choice of excipients is part of the normal knowledge of one skilled in the art, and will
mainly depend on the pharmaceutical and/or dermocosmetic form chosen.
For example, a cream can be prepared by incorporating the anti-bacterial composition of the
present invention in a topical carrier consisting of liquid paraffin, dispersed in an aqueous
medium by means of lubricants. An ointment can be prepared by mixing TSP with a topical
carrier such as mineral oil or wax. A gel can be prepared by mixing TSP with a topical
carrier containing a gelling agent.
The pharmaceutical and/or dermocosmetic composition according to the invention may also
be a, woven or non-woven, material coated and/or impregnated with a mixture of the anti-
bacterial composition with a suitable carrier or a matrix in which the anti-bacterial
composition is dispersed so that it comes into contact with the skin for transdermal
administration. Specific examples are bandage, gauze, towelettes, etc.
The choice of type of pharmaceutical and/or dermocosmetic form will depend mainly on the
area to be treated and is part of the normal knowledge of one skilled in the art. For example,
a gum or mouthwash may be more suitable to treat the oral cavity, whereas a cream,
ointment, lotion or towelettes may be suitable for the skin of the face.
The term “skin” is used according to the present in its conventional meaning, namely an
external organ including the epithelial tissue. The term “mucosa” is also used with its usual
meaning, which relates to all the mucosal barriers in the body, such as the gastrointestinal,
pulmonary, sublingual, buccal, rectal, vaginal, nasal, urethral and ocular barriers.
The compositions according to the invention are preferably applied by topical
administration directly to the area of the skin or mucosa which presents, or is assumed to
present, a bacterial infection or other disorders caused by the presence of microbes. The
infection often originates in a part of the skin or mucosa which presents a lesion, such as a
wound, laceration or burn. In such case, the composition according to the invention can be
applied directly to the lesion and/or the surrounding area.
The compositions of the present invention can also be used in the treatment and/or
prevention of several disorders of the skin and mucosa, which are known to be caused by
bacteria, for example, psoriasis, eczema, acne, etc. Other treatments may include wound
care, and burn care, etc.
Anti-Bacterial Activity of Compositions
The anti-bacterial activity of a candidate composition can be tested using standard
techniques known in the art. As is known in the art, anti-bacterial activity of a composition
or composition may result in the killing of bacterial cells (i.e. bacteriocidal activity), or it
may result in the slowing or arrest of the growth of bacterial cells (i.e. bacteriostatic
activity). Thus the compositions of the present may be bacteriocidal and/or bacteriostatic.
Compositions of the present invention that slow or arrest bacterial cell growth may be useful
in combination treatments with other known anti-bacterial agents.
In vitro Testing
In vitro methods of determining the ability of candidate compositions to inhibit, prevent or
eradicate the growth of bacterial cells are well-known in the art. In general, these methods
involve contacting a culture of the cells of interest with various concentrations of the
candidate composition and monitoring the growth of the cell culture relative to an untreated
control culture. A second control culture comprising cells contacted with a known anti-
bacterial agent may also be included in such tests, if desired.
Anti-bacterial effects can be expressed as the percentage (%) inhibition of growth of a given
micro-organism over a pre-determined period of time by treatment with a single
concentration of a candidate composition. This method provides a rapid method of assessing
the ability of a composition to inhibit bacterial growth, for example, prior to conducting
more in-depth tests, such as MIC determinations or in vivo testing. An example of such an
testing is in-vitro Time-Kill Method which is well known in the art.
Toxicity Testing
It is important that the anti-bacterial compositions of the present invention exhibit low
toxicity.
In vitro acute toxicity testing of a composition of the present invention can be performed
using mammalian cell lines (see, for example, Ekwall, B., Ann. N.Y. Acad. Sci., (1983)
407:64-77). Selection of an appropriate cell line is dependent on the potential application of
the candidate composition and can be readily determined by one skilled in the art.
In vivo toxicity testing can be performed by standard methodology, for example, by
injecting or introducing varying concentrations of the candidate composition into an
appropriate animal model. The composition can be injected once, or administration can be
repeated over several days. The toxic effects of the composition can be evaluated over an
appropriate time period by monitoring the general health and body weight of the animals.
After the completion of the period of assessment, the animals can be sacrificed and the
appearance and weight of the relevant organs determined.
In vivo Testing
The ability of a test composition to act as an anti-bacterial agent can also be tested in vivo
using standard techniques. A number of animal models are known in the art that are suitable
for testing the activity of anti-bacterial compositions and are readily available.
Methods for conducting in vivo tests to determine the activity of anti-bacterial compositions
are well-known in the art. Typically, in vivo testing comprises introducing a selected micro-
organism into the appropriate animal model in a sufficient amount to cause infection,
followed by administration of one or more doses of the test composition. Methods of
administration will vary depending on the composition being employed, but can be, for
example, by way of bolus infusion into a suitable vein (such as the tail vein of mice or rats),
or by oral administration. Animals treated with a known anti-bacterial agent and/or with a
saline or buffer control solution serve as controls. Repeat doses of the test composition may
be administered to the animal, if necessary, at appropriate time intervals. The animals are
subsequently monitored daily for mortality.
Additional Tests
In addition to the above tests, the compositions of the invention can be submitted to other
standard tests, such as stability tests, bioavailability tests and the like. As will be readily
apparent to one skilled in the art, compositions in accordance with the present invention will
need to meet certain criteria in order to be suitable for human use and to meet regulatory
requirements. Thus, once a composition of the invention has been found to be suitable for
animal administration, standard in vitro and in vivo tests can be conducted to determine
information about the metabolism and pharmacokinetic (PK) of the compositions and
combinations (including data on drug-drug interactions where appropriate) which can be
used to design human clinical trials.
To gain a better understanding of the invention described herein, the following examples are
set forth. It should be understood that these examples are for illustrative purposes only.
Therefore they should not limit the scope of the invention in any way.
EXAMPLES
An exemplary composition of the present invention (composition A) was prepared by
mixing 50 grams of lactic acid, 105 grams of undecylenic acid and 25 grams of AMP-95%.
Composition A is soluble in most solvents (i.e., acetone, chloroform, methanol, ethanol,
benzene, DMAC, DMSO) with no loss of bioactivity and can be solubilized in aqueous
medium using a co-solvent system. Physical properties of the composition remained the
same after heating (no color change or gelation or evaporation was observed).
Example 1: In vitro Inhibition of Gram Positive Bacteria
The anti-bacterial effect of the exemplary composition A was evaluated at two different
concentrations versus suspensions of Enterococcus faecalis VRE (ATCC #51575) and
Staphylococcus aureus aureus MRSA (ATCC #33591).
Testing was conducted in accordance with a Non-GLP evaluation of one test material for
its antibacterial properties when challenged with two microorganism species using an in-
vitro Time-Kill Method. The test material was prepared at two different concentrations
prior to evaluation. Test Solution #1 was prepared by diluting the test material in the ratio
of 1.0 mL of concentrated test material to 100 mL of sterile Water-for-Irrigation, USP
(WFI) (1:100 [v/v] dilution). Test Solution #2 was prepared by diluting the test material in
the ratio of 0.1 mL of Composition A to 100 mL of WFI (1:1,000 [v/v] dilution). A 0.1
mL aliquot of a challenge suspension was inoculated into a test tube containing 9.9 mL of
a Test Solution and mixed thoroughly using a vortex mixer. Each challenge suspension
was exposed to each Test Solution for 10 minutes, timed using a calibrated minute/second
timer. After the exposure time had elapsed, a 1.0 mL aliquot was transferred from the
tube containing Test Solution/inoculum into a separate sterile test tube containing 9.0
mL of Butterfield's Phosphate Buffer solution with product neutralizers (BBP++), and
mixed thoroughly using a vortex mixer. Ten-fold dilutions were prepared in neutralizing
solution, mixing thoroughly using a vortex mixer between dilutions. 1.0 mL and/or 0.1
mL aliquots of each dilution were pour-plated, in duplicate, using Tryptic Soy Agar with
product neutralizers (TSA+).
Tables 1 and 2 present the initial population (CFU/mL) and post-exposure populations
(CFU/mL) of each challenge species, and the Log and percent reductions produced by
each Test Solution following a 10-minute exposure.
Table 1
Test Solution #1 – Composition A
1:100 [v/v] dilution
Post-
Inoculum Level
Microorganism Species Exposure Log Percent
(CFU/mL) Exposure
(ATCC #) Reduction
Time Population Reduction
Enterococcus faecalis
VRE (ATCC #51575) 7 10 minutes 1 6.5563 99.9999%
3.60 X 10 < 1.00 X 10
Staphylococcus aureus
aureus
MRSA (ATCC #33591) 10 minutes 5.8712 99.9999%
1.1150 X 10 1.50 X 10
TABLE 2
Test Solution #2- Composition A
1:1,000 [v/v] dilution
Post-Exposure
Inoculum
Exposure
Microorganism Species Level Population Log Percent
Enterococcus faecalis
7 10 minutes 1 6.5563
VRE (ATCC #51575) 99.9999%
3.60 X 10 < 1.00 X 10
Staphylococcus aureus
aureus
7 10 minutes 1 6.0473 99.9999%
1.1150 X 10 < 1.00 X 10
MRSA (ATCC #33591)
Notes:
1. Concentrated Test Composition was diluted with sterile Water-for-
Irrigation, USP, prior to evaluation.
Example 2: In vitro Inhibition of Gram Negative Bacteria
The anti-bacterial effect of the test material, Composition A, was evaluated at two
different concentrations versus suspensions of Escherichia coli (ATCC #BAA-2469) and
Klebsiella pneumoniae pneumoniae (ATCC #BAA-2146).
Testing was conducted in accordance with a Non-GLP evaluation of one test material for
its antibacterial properties when challenged with two microorganism species using an in-
vitro Time-Kill Method. The test material was prepared at two different concentrations
prior to evaluation. Test Solution #1 was prepared by diluting the test material
(Composition A) in the ratio of 1.0 mL of concentrated test material to 100 mL of sterile
Water-for-Irrigation, USP (WFI) (1:100 [v/v] dilution). Test Solution #2 was prepared by
diluting the test material in the ratio of 0.l mL of concentrated test material to 100 mL of
WFI (1:1,000 [v/v] dilution). A 0.1 mL aliquot of a challenge suspension was inoculated
into a test tube containing 9.9 mL of a test solution and mixed thoroughly using a vortex
mixer. Each challenge suspension was exposed to each Test Solution for 10 minutes,
timed using a calibrated minute/second timer. After the exposure time had elapsed, a 1.0
mL aliquot was transferred from the tube containing Test Solution/inoculum into a
separate sterile test tube containing 9.0 mL of Butterfield's Phosphate Buffer solution
with product neutralizers (BBP++), and mixed thoroughly using a vortex mixer. Ten-fold
dilutions were prepared in neutralizing solution, mixing thoroughly using a vortex mixer
between dilutions. 1.0 mL and/or 0.1 mL aliquots of each dilution were pour-plated, in
duplicate, using Tryptic Soy Agar with product neutralizers (TSA+).
Tables 3 and 4 present the initial population (CFU/mL) and post-exposure populations
(CFU/mL) of each challenge species, and the Log and percent reductions produced by
each Test Solution following a 10-minute exposure.
TABLE 3
Test Solution #1 – Composition A
1:100 [v/v] dilution
Microorganism Species Exposure Log Percent
Inoculum Post-Exposure
(ATCC #) Level Time Population Reduction Reduction
Escherichia coli 6 10 minutes 1 5.9269 99.9999%
8.450 X 10 < 1.00 X 10
(ATCC #BAA-2469)
Klebsiella pneumoniae 7 10 minutes 1 6.3711 99.9999%
2.350 X 10
< 1.00 X 10
pneumoniae
(ATCC #BAA-2146)
TABLE 4
Test Solution #2- Composition A
1:1,000 [v/v] dilution
Inoculum Post-Exposure
Microorganism Species Exposure Logw Percent
Level Population
(ATCC #) (CFU/mL) Time (CFU/mL) Reduction Reduction
Escherichia coli 6 10 minutes 1 5.9269 99.9999%
8.450 X 10 < 1.00 X 10
(ATCC #BAA-2469)
7 10 minutes 1 6.3711 99.9999%
Klebsiella pneumoniae
2.350 X 10 < 1.00 X 10
pneumoniae
(ATCC #BAA-2146)
Notes:
2. Concentrated Test Product (composition A) was diluted with sterile Water-
for-Irrigation, USP, prior to evaluation.
Example 3: Efficacy study of Anti-MRSA composition A on Animal model
Efficacy study on the composition A was conducted in C57bl-6 Mice and Sprague Dawley
rats.
3a: Methicillin-resistant S. aureus (MRSA) intra-venous administration in mice (25
mice C57BL/6):
A suitable infectious dose of 2.4 x 10 CFU/ml was provided by 0.1 mL of bacterial stock
injected intravenously in each mouse. Oral or IP administration of the composition A
occurred 15 minutes after injection of the bacteria and once daily for a further five days.
Five groups of five C57BL/6 Mice each were used and the groups and treatment dosage
dose were as shown in Table 5:
TABLE 5
Group Treatment Dosage Dose Level Dose Number of
mice Volume Animals
1 Control na na 400 ul/200 g 5
saline (oral
gavage)
2 IP 500 mg/kg MTD 10 ul/20 g 10
3 oral gavage 2000 mg/kg MTD 40 ul/20 g 10
na = not applicable
Results
Control Group 1: All 5 mice from the control group died consecutively on days 5, 6, and 7
from bacterial infections. One day prior to death, there were observations of sickness,
including apatia, restriction of movement, and loss of appetite. They were found dead
overnight. Histological changes could not be observed from the carcasses.
IP Group 2: In the itraperitoneal group, two of ten mice (20%) died on the third day of the
study after the third injection of High Dose (LD50) 500mg /kg Composition A. The cause of
death was not confirmed. The remainder of the mice (80%) survived post day 5 including
MRSA administration with no apparent sickness.
Gavage Group 3: In the gavage group, two of ten mice (20%) died; one each on days 3 and
7. The remainder of the mice (80%) survived post day 5 including MRSA administration
with no apparent sickness.
3b: (MRSA) Intra-venous (tail vein) administration in mice (25 mice C57BL/6)
Mice were inoculated intravenously with 1x10 CFU/ml of MRSA. The test composition
was administered to the inoculated mice by oral gavage. At the end of study, post 14 days,
blood was collected and cultured for bacteria detection.
Five groups of five C57BL/6 Mice each were used and the groups were as follows:
1) 5 mice (G1) control (only MRSA)
2) 5 mice (G2) treatment 500 mg/kg of Composition A, once/day for 14 days IV
induction of MRSA
3) 5 mice (G3) treatment 100 mg/kg of Composition A, once/day for 14 days IV
induction of MRSA
4) 5 mice (G4) treatment 50 mg/kg of Composition A, once/day for 14 days IV
induction of MRSA
) 5 mice (G5) treatment 25 mg/kg of Composition A, once/day for 14 days IV
induction of MRSA
Results
Blood cell culture results for groups G1 to G5 are shown in Figures 1A to 1F. With the
exception of Group 1 all blood cultures from all dosed treatment animals did not show
any bacterial growth. In the control group G1, mouse no. 5 died on day 10, post IV
administration of Staphylococcus aureus. All the rest of the animals (four animals)
showed massive bacterial growth. The health of the animals in the treatment groups was
not affected.
4b: Rat full-thickness excision model on Sprague-Dawley Rats.
Procedure (summary):
a) Wound sites were prepared on the back of each anesthetized rat by exposing ~2 cm
of fascia.
b) The exposed fascia was inoculated with a 100-µL suspension of 10 CFU/mL of
ATCC USA300 S. aureus.
c) After 15 minutes, the wounds were treated with 0.4 ml of Composition A or with
sterile saline (recovery controls) and repeated daily for 5 consecutive days. Five days
following treatment, a swab was taken from the wound and cultured on tryptic soy agar,
incubated overnight at 35°C, and colonies were counted to determine organism survival.
d) Three groups of three adult male rats each were used and the groups were as follows:
Groups:
Total animals: 9 rats received topical or oral (gavage) administration of test composition or
saline control once daily for 5 days.
Group 1) 3 rats (control) received saline (400 uL/200 g rat); topical, 1x daily for 5 days
Group 2) 3 rats treated with 2000 mg/kg Composition A (400 uL/200 g rat); topical 1x
daily/5 days
Group 3) 3 rats treated with 500 mg/kg Composition A (100 uL/200 g rat); oral
administration 1x daily/5 days
Group Assignments and Dose Levels
Group Treatment Dosage Dose Dose Number of
rats Level Volume Animals
1 Rat wound topical 2000 mg/kg ND 400 uL/200 gr 3
application rat
2 Rat wound oral 500 mg/kg ND 100 uL/200 gr 3
gavage rat
3 Rat wound control 2000 mg/kg na 400 uL/200 gr 3
(saline) rat
ND = not determined; na = not applicable
Results
Control Group
All animals showed evidence for an active bacterial infection in the area of the wound. A
thick yellow/green opaque liquid was produced in the infected tissue, consisting of dead
white blood cells and bacteria with tissue debris and serum. This was observed in all 3 rats
from control group. All animals survived.
Topical Group
In the topical application group (see images in appendix for Group 2), there was a significant
improvement in the appearance of the wound, showing no puss or any kind of secretion
compared to the “no treatment” group (saline), where the wound showed infection. Slight
necrosis was observed post day 5 in “treatment group” (topical application). This effect may
be due to the test material (2000mg/kg treatment with repeated 5 day administration). No
signs of sickness were observe in the topical application group.
Gavage Group
In the gavage group, all rats died on days 3, 4, and 5. The dose of 500 mg /kg may have
produced the death of rats by the accumulation of the composition in repeated
administration.
4b: Rat full-thickness excision model on Sprague-Dawley Rats.
Wound sites were prepared on the back of each anesthetized rat by exposing ~2 cm2 of
fascia. Five adult male Sprague-Dawley rats, with one wound site each were used for each
treatment group. The exposed fascia was inoculated with a 100-µL suspension of 1 x 10
CFU/mL of ATCC us, 300 S. aureus. After 15 minutes, the wounds were treated, via
topical application, with 0.4 ml of Composition A or with sterile saline (recovery controls)
and repeated daily for 14 consecutive days. Fourteen days following treatment, a swab taken
from the wound was cultured on tryptic soy agar, incubated overnight at 35°C, and colonies
were counted to determine organism survival.
Five groups of five Sprague-Dawley Rats each were used and the groups were as follows:
1) 5 Rats (G1) control (only MRSA)
2) 5 Rats (G2) treatment 25 mg/kg of Composition A, once/day for 14 days
direct wound application induction of MRSA
3) 5 Rats (G3) treatment 50 mg/kg of Composition A, once/day for 14 days
direct wound application induction of MRSA
4) 5 Rats (G4) treatment 100 mg/kg of Composition A, once/day for 14 days
direct wound application induction of MRSA
) 5 Rats (G5) treatment 500 mg/kg of Composition A, once/day for 14 days
direct wound application induction of MRSA
At the end, post 14 days, a swab from wound was collected and cultured for bacteria
detection.
Results
In Group 1, multiple colonies were present in all five blood cell culture agar plates from all
five rats. In Group 2, the blood agar culture presents two small colonies from rat no. 7, and
rat no. 9. In Group 3, the blood agar culture plates showed presence of four small colonies
from rat nos. 12 to 14. In Group 1, zero colonies were observed in the blood agar culture
plates.
All groups with treated wounds show no sign of infection. All wounds were 100%
healed. In the control group the wound was infected.
Example 5: Oral Dose and Topical Application Toxicity Study
Repeated dose oral toxicity and topical application toxicity study was conducted in BALB/C
mice to ascertain the safety of Composition A following repeated oral or topical
administration.
5a: Two Weeks Repeated Dose Oral Toxicity Study
Procedure
Composition A was administered to BALB/C mice (n = 5 males and 5 females per group)
daily by oral gavage at doses of 0 mg/kg/day (40 μl/20g olive oil), 1000 mg/kg/day (40
μl/20g composition A), 300 mg/kg/day (40 μl/20g composition A), and 100 mg/kg/day (40
μl/20g composition A) for 14 days.
During the dosing period, the animals were observed daily immediately after administration
and again 6 hours post administration for clinical signs of toxicity.
Animals that died or were terminated in a moribund state during the test period were
necropsied, the organs weighed, and collected for histopathological analysis. Surviving
animals were terminated 24 hours after the necropsied, the organs weighed, and fixed for
histopathological analysis.
Blood and urine was collected and analyzed from each animal at time 0 (pre-dose), Day 1
(24 hrs.), Day 7, and Day 14 (end of study) for hematology, CBC, blood chemistry and
urinalysis.
Results
Oral administration of the test composition at doses up to 1000 mg/kg/day showed no effect
on body weight or body weight gain in either male or female mice.
Hematology-Some significantly different numbers at any dose are not drug related.
Clinical Chemistry- There was no drug effect at any dose
Urine Analysis- There was no drug effect at any dose or time point
Gross Pathology- We concluded that the observed differences were not related to the test
composition
Histopathology-
Some findings or incidental findings were not related to composition A at any doses.
Throughout the study duration of 14 days, no sickness was observed in the mice.
The above results confirmed that oral administration of Composition A in a high dose (1000
mg/kg) did not produce any adverse effect.
5b: Two Weeks Repeated Dose Topical Application Toxicity Study
Procedure
Composition A was administered to BALB/c mice (n = 5 males and 5 females per group)
daily by topical application at doses of 0 mg/kg/day (40 μL/20g olive oil), 1000 mg/kg/day
(40 μL/20g composition A), 300 mg/kg/day (40 μL/20g composition A), and 100 mg/kg/day
(40 μL/20g composition A) for 14 days.
Each mouse was placed under isofluorane gas anesthesia; on the back of the shoulder, the
fur was clipped and a 3-4 mm circular section of skin was removed creating an artificial
wound. The composition was applied daily for 14 days over the created wound. The wound
area was measured on day 0, day 7, and day 14.
During the dosing period, the animals were observed daily immediately after administration
and again 6 hours post administration for clinical signs of toxicity.
Animals that died or were terminated in a moribund state during the test period were
necropsied, the organs weighed, and collected for histopathological analysis. Surviving
animals were terminated 24 hours after the last dose, necropsied, the organs weighed, and
fixed for histopathological analysis.
Blood and urine was collected and analyzed from each animal at time 0 (pre-dose), Day 1
(24 hrs.), Day 7, and Day 14 (end of study) for hematology, CBC, blood chemistry and
urinalysis.
RESULTS
Topical administration of the test composition at doses up to (1000 mg/kg) showed no effect
on body weight or body weight gain in both male and female mice.
Hematology- Some significantly different numbers at any dose are not drug related.
Clinical Chemistry- There was no drug effect at any dose.
Urine Analysis- There was no drug effect at any dose or time point.
Gross Pathology- We concluded that the observed differences were not related to the test
composition.
Histopathology- Some findings or incidental findings were not related to composition A at
any doses.
Throughout the study duration of 14 days, no sickness in the mice was observed
The above results confirmed that topical application of Composition A in a high dose (1000
mg/kg) did not produce any adverse effect.
Example 6: Toxicokinetics Study for Oral Dose and Topical Application Toxicity
Toxicokinetics study for two weeks repeat dose oral toxicity and topical application toxicity
of anti-bacterial Composition A was conducted in BALB/C mice to determine the
amount/level of undecylenic acid analyte from Composition A in K2EDTA plasma samples
in mice at different time points following the administration.
An LC/MS/MS procedure (M150911) was developed for the quantification of undecylenic
acid in mouse K2EDTA plasma. Undecylenic acid and the internal standard (9-Decenoic
acid) were isolated from mouse K2EDTA plasma by liquid-liquid extraction (MTBE was
used as solvent). The extracted samples were transferred to clean injection vials. A 5 μL
sample was injected into the LC/MS/MS system for analysis. The standard curve range was
0.5 - 100 μg/mL of undecylenic acid in K2EDTA plasma. A 50 μL K2EDTA plasma sample
aliquot was used for sample preparation and analysis. All study samples were within the
stability parameters established during validation of the method. The stability parameters
include reinjection stability of extracted samples for up to 29.8 hours on autosampler at
°C; refrigeration stability of extracted samples for up to 69.4 hours at 2-8°C; bench-top
stability of unextracted samples for up to 5.5 hours; and freeze-thaw stability for up to four
freeze-thaw cycles, and long-term storage stability of the QC samples for up to 25 days at -
70°C (long enough to cover the study sample storage period).
Each analytical batch contained one set of calibration standards placed at the beginning of
the run. The peak areas for undecylenic acid and the internal standard were determined
using the Analyst software. A quadratic regression (weighted 1/x2) was applied to a plot of
the peak area ratio versus concentration for the standards to obtain the calibration curve. The
sample concentrations are calculated from the curve parameters as performed by the Analyst
software version 1.4.2.
6a: Toxicokinetics for Oral Dose
Procedure
Composition A was administered to BALB/C mice (n = 18 males and 18 females per group)
by oral gavage at doses of 0 mg/kg/day (40 μl olive oil), 1000 mg/kg/day (40 μl composition
A), 300 mg/kg/day (40 μl composition A), and 100 mg/kg/day (40 μl composition A) and
serial blood samples were taken from six mice per time point (3, 6, 8, 12, and 24 hours) on
Day 1 and Day 14 of administration.
1. Group 1 Control – time 0. Blood samples were collected from six mice (3 males and
3 females).
2. Group 2 High Dose – 1000 mg/kg – time 3, 6, 8, 12, and 24 hours on Day 1 and Day
14 of administration. Blood samples from six mice (3 males and 3 females) were
collected at each time point.
3. Group 3 Medium Dose - 300mg/kg –time 3, 6, 8, 12, and 24 hours on Day 1 and Day
14 of administration. Blood samples from six mice (3 males and 3 females) were
collected at each time point.
4. Group 4 Low Dose - 100mg/kg –time 3, 6, 8, 12, and 24 hours on Day 1 and Day 14
of administration. Blood samples from six mice (3 males and 3 females) were
collected at each time point.
Blood was collected by cardiac puncture (approx. 500 μL), centrifuged, the plasma collected
and pooled at each time point, then frozen at - 80C for future analysis.
Results
Oral administration of the test composition at a dose of 100 mg/kg resulted in no detectable
analyte in the plasma of male mice 3 hours after administration. In female mice, one animal
showed detectable levels of the test composition at this same dose level.
Oral administration of the test composition at a dose of 300 mg/kg resulted in detectable
levels in the serum of both male and female mice three hours after administration. Serum
plasma analyte concentrations at the 3 hour time point was less than 3 times higher than the
serum analyte level seen in the one female mouse at the low dose (1.56 vs 2.35 ug/mL). By
six hours after administration, only two of three males or females had detectable serum
analyte levels while at 8 hours post dose, no males and one female had detectable analyte
plasma levels. Interestingly, one male also showed detectable analyte levels at 24 hours at
levels similar to that seen at 6 hours, however, serum samples collected at 8 and 12 hours
showed no detectable analyte levels.
Oral administration of the test composition at the highest dose level (1000 mg/kg/day)
resulted in detectable analyte levels in the serum in two of three males and all three females.
Analyte levels between these five animals were variable ranging from 0.66 to 6.57 ug/ml.
However, the highest value observed, 6.57 ug/mL was approximately 3 times greater than
the highest serum analyte level seen at the 300 mg/kg/day dose level sample. Sequential
serum samples with detectable analyte were present in two of the six animals tested. Of the
six animals tested, only one had three sequential serum samples with measurable analyte
levels. Consequently, no AUC determinations could be performed. In addition, due to the
limited number of animals and the variable nature of the values obtained, Cmax values are
also not reliably determinable.
6b: Toxicokinetics for Topical Application
Procedure
Composition A was administered to BALB/C mice (n = 18 males and 18 females per group)
by topical application at doses of 0 mg/kg/day (40 μl olive oil), 1000 mg/kg/day (40 μl
composition A), 300 mg/kg/day (40 μl composition A), and 100 mg/kg/day (40 μl
composition A) and serial blood samples were taken from six mice per time point (3, 6, 8,
12, and 24 hours) on Day 1 and Day 14 of administration.
1. Group 1 Control – time 0. Blood samples were collected from six mice (3 males and
3 females).
2. Group 2 High Dose – 1000 mg/kg – time 3, 6, 8, 12, and 24 hours on Day 1 and Day
14 of administration. Blood samples from six mice (3 males and 3 females) were
collected at each time point.
3. Group 3 Medium Dose - 300mg/kg –time 3, 6, 8, 12, and 24 hours on Day 1 and Day
14 of administration. Blood samples from six mice (3 males and 3 females) were
collected at each time point.
4. Group 4 Low Dose - 100mg/kg –time 3, 6, 8, 12, and 24 hours on Day 1 and Day 14
of administration. Blood samples from six mice (3 males and 3 females) were
collected at each time point. Blood was collected by cardiac puncture (approx. 500
μL), centrifuged, the plasma collected and pooled at each time point, then frozen at -
80C for future analysis.
Results
Application of test composition topically at a dose of 100 ug/kg/day resulted in no
detectable serum analyte levels in either male or female mice. At the 300 mg/kg/day dose
level, serum analyte levels were below the level of detection in the male mice. In the female
mice, at the 3 hour time point, two animals had detectable serum analyte levels. As these
values were approximately half of what was observed in female mice orally administered
the composition, it is possible that the serum analyte levels were secondary to grooming.
Further support for this hypothesis comes from the one male animal with detectable serum
analyte levels 3 hours after topical administration. In this case, the mouse had serum analyte
levels that were comparable to that seen with oral administration. Based on these data, it is
possible that the test composition is absorbed through the skin but it is equally likely that the
serum analyte levels seen following topical administration at the middle dose are the result
of the animals grooming.
At the 1000 mg/kg/day dose level, two males and two females had detectable serum analyte
levels 3 hours post application. The serum analyte levels were lower than that seen
following topical administration at the 300 mg/kg/day dose providing further support for
oral uptake secondary to grooming.
The results from toxicokinetics studies suggest that absorption either by the oral or topical
route appears to be limited. As a result, systemic exposures are also limited.
Example 7: Comparative Efficacy Study
Efficacy Study in comparison to leading anti-MRSA antibiotics was conducted in BALB /C
mice.
7a. Administration Route: Oral gavage
1) vancomycin
Group 1 (6 mice males)-MRSA Induction IP no treatment
Group 2 (6 mice males) -MRSA Induction IP- oral treatment for 7 days
Group 3 (6 mice males) -No Induction - oral treatment for 7 days
Group 4 (6 mice males) -MRSA Induction IP-oral treatment with composition A
2) clindamycine
Group 1 (6 mice males)-MRSA Induction IP no treatment
Group 2 (6 mice males) -MRSA Induction IP- oral treatment for 7 days
Group 3 (6 mice males) -No Induction - oral treatment for 7 days
Group 4 (6 mice males) -MRSA INDUCTION IP-oral treatment with composition A
3) erythromycine
Group 1 (6 mice males)-MRSA Induction IP no treatment
Group 2 (6 mice males) -MRSA Induction IP- oral treatment for 7 days
Group 3 (6 mice males) -No Induction - oral treatment for 7 days
Group 4 (6 mice males) -MRSA Induction IP-oral treatment with composition A
7b. Administration Route: Topical Application
1) bactroban
Group 1 (6 mice males)-MRSA Induction (wound application) no treatment
Group 2 (6 mice males) -MRSA Induction (wound application) - treatment for 7
days
Group 3 (6 mice males) -No Induction – topical application treatment for 7 days
Group 4 (6 mice males) -MRSA Induction (wound application) - treatment with
composition A
Dosage for Comparative Test
For Composition A Dose was 100mg/kg. For the antibiotics the dose was as per RX
prescription converted to mice Body Weights.
1-Erythromycin 250 mg/pt b.i.d. equals 2.1 mg/20 g mouse/day 300mg total/12mice
Erythromycin 500mg/pt b.i.d. equals 4.2 mg/20 g mouse/day
2-Clindamycin 150 mg/pt b.i.d. equals 1.25 mg/20 g mouse/day 200mg total/12 mice
Clincamycin 300 mg/pt b.i.d. equals 2.5 mg/20 g mouse/day
3-Vancomycine 250 mg/pt b.i.d. equals 2.1 mg/20 g mouse/day 300mg total/12 mice
4- A small amount (0.1 g) of Bactroban Ointment was applied to the affected area /20g
mice/day.
RESULTS
Blood cell culture results for the comparative tests are as discussed below:
1. Vancomycin Group
Group 1 - MRSA induction – No treatment: There was bacteria development from the blood
taken from mice no. 1, 4, 5, 6.
Group 2 – MRSA induction vancomycin treatment: There was bacterial growth one colony
from animal no. 4 blood culture.
Group 3 – NO MRSA induction vancomycin treatment; all probes negative.
Group 4 – MRSA induction Composition A treatment: Negative.
The comparison between the treatments shows a slight advantage for the Composition A
treatment, where no bacteria was found versus the vancomycin treatment that shows one
colony.
2. Erythromycin Group
Group 1 – MRSA induction No treatment: All six animals have positive colonies.
Group 2 – MRSA induction; Erythromycin treatment: show two colonies in mice nr.1 and
nr.2.
Group 3 – No MRSA treatment with erythromycin: all probes negative but the pictures
show some light reflection between probes 3 and 4, and, 5 and 6.
Group 4 – MRSA induction with treatment with composition A: All probes negative –
pictures show some light reflections.
The comparison between the treatment show a definite superior results in the groups treated
with Composition A (negative results) and erythromycin that presents 2 positive colonies.
3. Clindamycin Group
Group 1 – MRSA induction – No treatment: All samples show positive colonies.
Group 2 – MRSA induction – Clindamycin treatment: All samples show negative colonies
(light reflection effect at probe 1, 5 and 6).
Group 3 – No MRSA – Clindamycin treatment: All negative (light effects at samples 1, 2, 3
and 6).
Group 4 – MRSA induction Treatment with Composition A: All samples negative, light
effects at no. 6 and no. 2.
The comparison between the treatment with Clindamycin and Composition A show both a
positive effect.
4. Bactroban Group –topical application
Group 1 – MRSA induction – no treatment: all samples show positive colonies.
Group 2 – MRSA induction – Bactroban treatment: Blood probes negative, wound swab
positive in mouse nr. 4, (5 colonies).
Group 3 – no MRSA induction – Bactroban treatment: all negative.
Group 4 – MRSA induction – Composition A treatment: blood probes negative, one probe
positive from swab in animal nr. 2, (1 colony).
Comparison between Bactroban and Composition A topical application show a slight
advantage for Composition A (five colonies in Bactroban and one colony in Composition
In addition Composition A presents the advantage that it spreads and diffuses all over the
infected wound areas without touching the contaminated area, and can be applied by
droplets versus Bactroban that needs to be applied in direct contact with the wound on the
contaminated area. The Composition A used had the lowest concentration of 100mg/kg.
Example 7: OECD Bovine Corneal Opacity and Permeability Test (BCOP)
Composition A was tested for potential ocular irritation using an alternative to the Draize
methodology. This protocol is based on the methodology described in the current OECD
Guideline for the Testing of Chemicals #437.
Method:
Three bovine corneas per group were dosed with 0.75 ml of composition A, Minimal
Essential Media (MEM) (negative control), or 100% Ethanol (positive control). Following a
-minute exposure for each group of dosed corneas, opacity measurements and sodium
fluorescein permeability were determined. The results are summarized in Table 6:
TABLE 6
Treatment In Vitro Irritation Corrected Mean Corrected Mean
Score (IVIS) Opacity Score Optical Density
composition A 0.50 0.33 0.011
MEM 0.76 0.67 0.006*
(negative control)
100% Ethanol 32.34 22.66 0.645
(positive control)
Based on an In Vitro Irritation Score of less than 3, in accordance with EURL DB-ALM
protocol No. 127, Composition A was considered to be non-irritant.
Example 8: 3T3 Neutral Red Uptake Phototoxicity Assay
The cytotoxicity and phototoxicity of the test composition to 3T3 cells (in the presence or
absence of UVA light) was assessed by Neutral Red Uptake. The 3T3 Neutral Red Uptake
Phototoxicity Assay (3T3 NRU PT), based on the OECD Guideline for Testing of
Chemicals: No. 432, was designed to detect the phototoxicity induced by the combined
action of a test composition and solar-simulated UVA + visible light in an in vitro
cytotoxicity assay using the BALB/C 3T3 mouse fibroblast cell line as the test system.
The assay identifies aqueous-soluble compounds (or formulations) that have the potential to
exhibit in vivo phototoxicity after systemic application.
An Ultraviolet-Visible light (UV-VIS) spectral scan was performed on a solution containing
0.1% of the test composition in a solution of 1% DMSO/HBSS. The scan showed that most
of the absorbance occurred below the Ultraviolet A (UVA) and Ultraviolet B (UVB) regions
(OD280 to OD400) and should not have any impact on the results of the 3T3 assay. For both
the range-finding screen and the definitive test of the 3T3 assay, BALB/C 3T3 cells were
seeded in the central 60 wells of duplicate 96-well microplates and maintained in culture for
approximately 24 hours. The two 96-well plates were then preincubated with eight different
concentrations of the test composition for approximately one hour. After preincubation, one
plate was irradiated with a dose of 5 J/cm Solar Simulated Light (SSL, containing
wavelengths in the UVA and visible regions with >99% of UVB blocked out), while the
duplicate plate was kept in the dark (No SSL). After UV irradiation, the treatment medium
was replaced with culture medium and, after approximately 24 hours, cell viability was
determined by neutral red uptake for three hours.
A range finding screen was performed to determine the acceptable concentrations for the
definitive test. MS Excel® was used to calculate the EC50 values and Photo-Irritant Factor
(PIF) for the test article and the Chlorpromazine (CPZ) positive control in both the Screen
and the Definitive test. Results of the definitive test are summarized in Table 6:
TABLE 6
Test Concentration EC50 EC50 PIF
Composition Range Tested No SSL +SSL
composition A 0.0068-0.1% >0.1% >0.1% None
CPZ No SSL: 6.81-100 18.8 μg/ml 0.4 μg/ml 47.0
Positive Control μg/ml
+SSL: 0.22-3.16
μg/ml
Test Composition A had EC50 values of >0.1% for both No SSL and +SSL; therefore, the
Photo-Irritancy Factor (PIF) could not be calculated. This test composition therefore is not
considered to have phototoxic potential in the 3T3 Neutral Red Uptake Phototoxicity Test.
Example 9: MatTek EpiDerm™ Skin Irritation Test (SIT)
This test was conducted to predict dermal irritation potential of test articles in the context of
identification and classification of skin irritation hazard according to the European Union
(EU) classification (R38 or no label), United Nations Globally Harmonized System of
Classification and Labeling of Chemicals (GHS) classification system (Category 2 and non-
irritants), and OECD Guideline for the Testing of Chemicals No. 439 – In Vitro Skin
Irritation: Reconstructed Human Epidermis Test Method. This study was designed based on
MatTek protocol in vitro EpiDermTM Skin Irritation Test.
MatTek EpiDerm™ tissue samples were treated in triplicate with the test composition,
Negative Control and Positive Control for 60 minutes. Following treatment and subsequent
incubation time, the viability of the tissues was determined using Methyl thiazole
tetrazolium (MTT) uptake and reduction. The absorbance of each sample was measured at
540 nm. The viability was then expressed as a percent of control values. If the mean tissue
viability was ≤50%, the test material was classified as an irritant; if the mean tissue viability
was >50%, the test material was classified as a non-irritant. The results are summarized in
table 7:
TABLE 7
Test and Control Article Mean Tissue Viability Irritancy
Identity Classification
Composition A 106.7% Non-Irritant
Phosphate Buffered Saline 100.0% Non-Irritant
(Negative Control)
% Sodium Dodecyl Sulfate 3.1% Irritant
(Positive Control)
Example 10: Preservative Challenge Test
The USP-NF <51> - Preservative Challenge Test was conducted to evaluate the
antimicrobial activity of the test composition for use in cosmetics and personal care
products.
Table 8: Results of Challenge tests analysis
Micro-organism Initial inoculums 10 minutes after 7 days
innoculation after
Staphylococcus 1.6×10 <10
aureus (cfu/g)
Staphylococcus 7.3×10 <10 <10
aureus (cfu/g)
E. coli (cfu/g) 4.4×105 <10 <10
Pseudomonas 3.5×105 <10 <10
aeruginosa
(cfu/g)
Candida albicans 3.6×105 <10 <10
(cfu/g)
Aspergillus niger 6.2×105 <10 <10
(cfu/g)
Example 11: Evaluation antimicrobial activity of a known Tegaderm and Effect of
composition A
The cellulose part of Tegaderm 3584 from 3M was tested for antimicrobial activity, which
did not show any antimicrobial activity against various bacterial species. Introduction of
5mg of composition A to 3M cellulose fibre (500mg) of Tegaderm, resulted in elimination
of 99.99% of wide range of bacteria including E. Coli.
Example 12: Evaluation of antimicrobial activity of composition A incorporated paper
product via dilution test
a) 200 microliter of E. coli B was grown in 10 ml of TSB medium overnight. Serial
dilution test showed high E. coli activity (108 CFU/mL) in petri dish. 200 μL of E. coli B
and 200 μL of composition A were dispersed in 10 ml of TSB medium overnight. Serial
dilution test showed no E. coli activity, concluding that incorporation of composition A
resulted in 99.999% E. coli B and bacteriophage resistance E. coli B.
b) 0.4g spruce/pine/fir (SPF) pulp paper sheet patch containing 200 μL of composition
A was immersed in 10 mL TSB medium containing 200 μL E. coli. Serial dilution test
showed no E. Coli activity.
c) 0.4g SPF paper sheet patch containing 200 μL of composition A was immersed in
mL overnight cultured E. coli ( fully grown 108 CFU/ mL). Serial dilution test showed
four log of reduction in E. coli activity (correspond to 80% drop in E. coli activity.
Example 13: Evaluation of antimicrobial activity of composition A incorporated plastic
product via serial dilution test
1.0 g of polyethylene (PE, melting 90~100 °C, Mw of 4000) was heated to melt (110 °C),
then 500 µl of Composition A was added to PE melt solution. The mixture was placed in
flat petri dish to reach room temperature and solidified to film. About 0.5g of sample (PE-
composition A) was immersed in E. coli suspension overnight at 37 °C. Complete E. coli
removal was observed after serial dilution test (108 CFU/mL to Zero).
DSC analysis showed that composition A and PE are not miscible blend and as a result a complete
diffusion release of composition A was confirmed. Physical structure property of PE should remain
same (further DMA analysis is required to confirm it.)
SEM analysis of PE/composition A showed that composition A is uniformly embedded through PE
film.
Same results were obtained when composition A was mixed with PE having MW of about
125 k and 100K (complete removal of E. coli).
The term “comprising” as used in this specification and claims means “consisting at least in
part of”. When interpreting statements in this specification and claims which include the
term “comprising”, other features besides the features prefaced by this term in each
statement can also be present. Related terms such as “comprise” and “comprises” are to be
interpreted in similar manner.
In this specification where reference has been made to patent specifications, other external
documents, or other sources of information, this is generally for the purpose of providing a
context for discussing the features of the invention. Unless specifically stated otherwise,
reference to such external documents is not to be construed as an admission that such
documents, or such sources of information, in any jurisdiction, are prior art, or form part of
the common general knowledge in the art.
Claims (29)
1. An antibacterial composition comprising: a) about 50% to about 70% of an unsaturated fatty acid or a pharmaceutically acceptable salt thereof, by weight of the total weight of the composition, wherein the unsaturated fatty acid is undecylenic acid; b) about 20% to about 30% of lactic acid or a pharmaceutically acceptable salt thereof, by weight of the total weight of the composition; c) about 10% to about 15% of at least one amino alcohol, by weight of the total weight of the composition, wherein the amino alcohol has a formula: OH NH R C C R 1 3 2 4 wherein R and R are each independently H or alkyl, R and R are each H, 2 4 2 4 or R and R are each C -C alkyl, or R is methyl and R is CH OH; 1 6 2 wherein the composition is free of additional antimicrobial or biocidal agents.
2. The antibacterial composition according to claim 1, wherein undecylenic acid is about 55% to about 60%; and lactic acid is about 25% to about 30%.
3. The antibacterial composition according to claim 1 or 2, comprising; about 58% of undecylenic acid; about 28% of lactic acid; and about 14% the amino alcohol.
4. The antibacterial composition according to claim 1, wherein the amino alcohol is 2-aminomethylpropanol (AMP 95%).
5. The antibacterial composition according to any one of claims 1 to 4, wherein the composition is suspended or dispersed in water.
6. The antibacterial composition of any one of claims 1 to 5, further comprising one or more of a carrier, diluent, excipient, flavouring agent, solubilizer, lubricant, suspending agent, and binder.
7. A pharmaceutical formulation comprising a composition as defined in any one of claims 1 to 6, and a pharmaceutically acceptable carrier.
8. The pharmaceutical formulation according to claim 7, where said formulation is for topical administration.
9. The pharmaceutical formulation according to claim 8, where said formulation is in the form of a cream, lotion or a gel.
10. The pharmaceutical formulation according to claim 7, where said formulation is for oral administration.
11. Use of the composition of any one of claims 1 to 6 in the preparation of a formulation for inhibiting growth and/or proliferation of bacteria.
12. A method of killing and/or inhibiting the growth of microbes on a non-living substrate comprising applying an effective amount of the antibacterial composition as defined in any one of claims 1 to 6 to the substrate.
13. Use of the composition of any one of claims 1 to 6 in the preparation of a formulation for the treatment or prevention of a bacterial infection in a mammal in need thereof.
14. Use of the composition of any one of claims 1 to 6 for incorporation into a cosmetic product, personal care product, cleanser, polish, paint, spray, soap, detergent, paper product or plastic product.
15. Use of the composition of any one of claims 1 to 6 in the preparation of a formulation for the treatment or prevention of a bacterial infection, or a disease or disorder associated therewith, in a subject in need of such therapy.
16. The use according to claim 15, wherein said composition is for use in combination with one or more anti-microbial agent(s).
17. A transdermal patch comprising the composition as defined in any one of claims 1 to 6.
18. A personal care product comprising the antibacterial composition as defined in any one of claims 1 to 6.
19. The personal care product of claim 18, wherein said personal care product is a cosmetic product, soap, deodorant, shampoo, mouthwash or toothpaste.
20. A household product comprising the antibacterial composition as defined in any one of claims 1 to 6.
21. The household product of claim 20, wherein said household product is a cleanser, polish, paint, spray, soap, or detergent.
22. A paper product comprising the antibacterial composition as defined in any one of claims 1 to 6.
23. A plastic product comprising the antibacterial composition as defined in any one of claims 1 to 6.
24. The antibacterial composition according to any one of claims 1 to 6, substantially as herein described with reference to any example thereof.
25. The pharmaceutical formulation according to any one of claims 7 to 10, substantially as herein described with reference to any example thereof.
26. Use according to any one of claims 11 or 13 to 16, substantially as herein described with reference to any example thereof.
27. A method according to claim 12, substantially as herein described with reference to any example thereof.
28. A transdermal patch according to claim 17, substantially as herein described with reference to any example thereof.
29. A product according to any one of claims 18 to 23, substantially as herein described with reference to any example thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562106816P | 2015-01-23 | 2015-01-23 | |
US62/106,816 | 2015-01-23 | ||
PCT/CA2016/050055 WO2016115639A1 (en) | 2015-01-23 | 2016-01-22 | Anti-bacterial compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ734881A NZ734881A (en) | 2021-09-24 |
NZ734881B2 true NZ734881B2 (en) | 2022-01-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11363814B2 (en) | Anti-bacterial compositions | |
AU784390B2 (en) | Therapeutic antimicrobial compositions | |
EP2775838B1 (en) | Aqueous antimicrobial composition containing coniferous resin acids | |
KR20150097560A (en) | Botanical antimicrobial compositions | |
JPH11322591A (en) | Antiseptic microbicide and composition for applying to human body | |
KR20110133467A (en) | Antimicrobial foamable soaps | |
JP2693859B2 (en) | Acne vulgaris skin external preparation for acne | |
AU2004287281A1 (en) | Disinfecting composition and methods of making and using same | |
WO2006087569A2 (en) | Antimicrobial composition comprising an extract of tarchonanthus camphoratus | |
JP2011074082A (en) | Antiseptic sterilizer and composition for application to human body | |
AU2008360632A1 (en) | Gentle, non-irritating, non-alcohoholic skin disinfectant | |
US4885310A (en) | Anti-fungal methods and agent | |
WO2013192034A2 (en) | Sanitizer compositions comprising alcohol and an antimicrobial efficacy enhancer | |
WO2013191565A1 (en) | Antimicrobial composition and its method of use | |
KR20100088878A (en) | Cleanser composition containing natural anti-bacterial components | |
US20230301884A1 (en) | Antiseptic compositions | |
WO2004105492A1 (en) | Aqueous compositions for disinfection and/or sterilization | |
NZ734881B2 (en) | Anti-bacterial compositions | |
KR20230004974A (en) | Antibacterial and Preservative Compositions | |
US20230126284A1 (en) | Antiseptic compositions | |
JPH11199476A (en) | Composition for disinfection and/or sterilization | |
CA3228070A1 (en) | Anti-fungal compositions | |
WO2024028179A1 (en) | Biocidal composition | |
KR20220014613A (en) | Composition for Controlling Microflora | |
KR20230004973A (en) | Antibacterial and Preservative Compositions |